Resverlogix - President and CEO, Donald McCaffrey (left)
President and CEO, Donald McCaffrey (left)
Source: Resverlogix
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Resverlogix (RVX) has partnered with EVERSANA to launch Apabetalone for COVID-19 in the United States and Canada
  • The company will utilize EVERSANA’s fully integrated commercialization services, including compliance and clinical and commercial field teams
  • The companies may expand to additional global markets as Emergency Use Authorization and/or a New Drug Application is approved
  • EVERSANA is a leading provider of global services to the life sciences industry
  • Resverlogix is developing Apabetalone (RVX-208), a first-in-class small molecule that acts as a selective BET inhibitor
  • Resverlogix (RVX) is up by 1.09 per cent and is currently trading at $0.93 per share

Resverlogix (RVX) has partnered with EVERSANA to launch Apabetalone for COVID-19 in the United States and Canada.

Resverlogix will utilize EVERSANA’s fully integrated commercialization services, including market access, agency services, clinical and commercial field teams, medical science liaisons, channel management, patient services, health economics and outcomes research, and compliance, with each service optimized by data and predictive analytics.

The companies may expand to additional global markets as Emergency Use Authorization and/or a New Drug Application is approved.

Apabetalone is an investigational phase 3 clinical candidate with the potential to combat COVID-19 through a unique dual mechanism. First, Apabetalone treatment prevents SARS-CoV-2 from infecting human cells; and second, it reduces inflammation and the cytokine storm response, which can result in organ damage and long-term negative impacts. 

Donald McCaffrey, President and CEO of Resverlogix, commented,

“With EVERSANA’s integrated commercialization solution, we are poised to swiftly and efficiently deliver Apabetalone to patients who desperately need it. We are proud to be on the front line with the global scientific medical community as we fight the ongoing threat of this and future pandemics.”

Jim Lang, CEO of EVERSANA, added,

“We believe in Apabetalone’s potential to save the lives of patients still facing the tragic impact of COVID-19 and its numerous growing variants as well as the millions of patients facing multiple diseases that have the potential to be treated by this much-needed therapy. Our complete end-to-end commercialization engine is mobilized and ready to move swiftly in anticipation of authorizations and approvals.”

EVERSANA is a leading provider of global services to the life sciences industry.

Resverlogix is developing Apabetalone (RVX-208), a first-in-class small molecule that acts as a selective BET (bromodomain and extra-terminal) inhibitor.

Resverlogix (RVX) is up by 1.09 per cent and is currently trading at $0.93 per share as of 9:52 am ET.

More From The Market Herald

" Hemostemix (TSXV:HEM) announces non-brokered private placement

Hemostemix (HEM) has announced a non-brokered private placement of up to 15 million units.
WELL Health - Chairman & CEO Hamed Shahbazi

" WELL Health (TSX:WELL) closes $34.5M public offering

WELL Health Technologies Corp. (WELL) has completed a bought deal public offering for proceeds of $34.5 million.

" Simply Better Brands (TSXV:SBBC) enters the weight loss category

Simply Better Brands (SBBC) has launched its entry into the weight loss category with a PureKana Keto Gummy.

" Cardiol Therapeutics (TSX:CRDL) appoints new directors

Cardiol Therapeutics (CRDL) has appointed Teri Loxam and Chris Waddick to its Board of Directors, effective immediately.